NATCO updates on USFDA inspection at its Kothur Formulation Facility
Natco Pharma Ltd has informed BSE regarding a Press Release dated January 25, 2017, titled "NATCO updates on USFDA inspection at its Kothur Formulation Facility".25-01-2017
25-01-2017
Statement of Investor Complaint under Reg. 13(3) of SEBI (LODR) Regulations, 2015 for Quarter ended December 31, 2016
Natco Pharma Ltd has informed BSE regarding Quarterly Statement on Investor Complaints / Grievances Redressal Mechanism for the Quarter ended December 31, 2016, under Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.10-01-2017
Shareholding for the Period Ended December 31, 2016
Natco Pharma Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here07-01-2017
Natco receives US FDA approval for cancer drug bendamustine
The approved product is generic version of Treanda, which has annual sales of about $ 133 mn in US07-01-2017
Natco may launch leukaemia drug in US market by Nov 2019
Following the approval from the US Food and Drug Administration for its generic version of Bendamustine Hydrochloride powder for injection, 25 mg/vial and 100 mg/vial (singe-dose vial), Natco Pharma...06-01-2017
Natco receives final approval for Generic Bendamustine HCL Powder for USA Market
Natco Pharma Ltd has informed BSE regarding a Press Release dated January 06, 2017 titled "Natco receives final approval for Generic Bendamustine HCL Powder for USA Market".06-01-2017
Natco Pharma unveils generic version of Hepatitis C drug in Nepal
Natco Pharma today announced the launch of the first generic version of Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose combination in Nepal. Sofosbuvir 400mg/Velpatasvir 100 mg fixed dose...02-01-2017
NATCO launches VELPANAT in Nepal- 1st generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination medicine in the country
Natco Pharma Ltd has informed BSE regarding a Press Release dated January 02, 2017 titled "NATCO launches VELPANAT in Nepal- 1st generic version of Sofosbuvir 400mg/Velpatasvir 100mg fixed dose combination medicine in the country".02-01-2017